Navigation Links
Combining CT, FDG-PET provides more accurate treatments for head and neck cancer patients
Date:4/29/2011

Combining computerized tomography (CT) with fluorodeoxyglucose positron emission tomography (FDG-PET) images results in significantly more defined tumor outlines and potentially different treatment options in head and neck cancer patients compared to using CT alone, according to research presented today, at the Cancer Imaging and Radiation Therapy Symposium in Atlanta. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiological Society of North America (RSNA).

CT is the standard method for determining tumor delineation before deciding head and neck cancer treatmenttypically intensity modulated radiation therapy. However, FDG-PET is an imaging method that uses a radioactive product combined with sugar and can produce better defined outlines of the tumor.

Researchers sought to determine the significance of combining CT and FDG-PET when determining tumor delineation and treatment for head and neck cancer patients.

In this trial, 327 patients were treated with IMRT for head and neck cancer. Based on the combined approach of the CT-scan and FDG-PET, the researchers noticed a change in the delineation of the tumor in one out of three patients, resulting in 10 percent of patients' treatment being changed and 33 percent of patients having their treatment adjusted.

In 17 percent of the patients, the primary tumor was not visible on the CT-scan alone, mostly due to dental inlays.

"We expected there to be an improved delineation of the tumor," Homan Dehnad, MD, a study author and radiation oncologist at Utrecht University Medical Center in Utrecht, Netherlands, said. "However, we never expected it to have such an influence on the treatment options for patients. Each dedicated institute dealing with head and neck cancer should be equipped with multi-imaged facilities."


'/>"/>

Contact: Beth Bukata
bethb@astro.org
American Society for Radiation Oncology
Source:Eurekalert

Page: 1

Related medicine news :

1. Combining MEK and PI3K inhibitors appears encouraging in a safety study with early signs of anti-tumor activity
2. Combining 2 peptide inhibitors might block tumor growth
3. Visual prostheses: Symposium to explore combining functional endpoints
4. Study provides molecular rationale for combining targeted agents to treat breast cancer
5. Combining radiation therapy, chemotherapy safely treats head and neck cancer patients
6. Combining medication and psychosocial treatments may benefit patients with early-stage schizophrenia
7. Combining resistance and endurance training best for heart health
8. FDG-PET/CT plays a definite role in detecting colorectal cancer recurrences
9. Teachers-based intervention provides stress resistance in war-exposed children
10. Discovery of 2 new genes provides hope for stemming Staph infections
11. Study provides first link between 2 major Parkinsons genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... (PRWEB) , ... April 26, ... ... which provides an agile ecosystem and domain expertise for sponsors and CROs ... randomization and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... ... April 25, 2017 , ... Coalition ... for Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor Therapeutics ... HOPE clinical trial in Duchenne announced today. , Coalition Duchenne funded studies ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting new ... in Lutz, FL. With the help of this highly-effective, yet convenient system, patients ... complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara ...
(Date:4/25/2017)... ... 2017 , ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace ... help but be heartened by the industry’s current surge. But another thing that unifies ... smell.” At last they can simply, safely and effectively end their aroma anguish ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... products, is introducing Flexadin UCII, part of the EQUISTRO line, at this week’s ... health in horses at the immunologic level. , The scientifically-developed Flexadin UCII supports ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... , April 24, 2017 Solentim, ... today announced the addition of a major new ... In-situ Plate Seeding,). The VIPS has been developed ... 384 well microplates as part of the process ... offers a simple and more reliable solution when ...
(Date:4/20/2017)... PLANO, Texas , April 20, 2017  Vivify ... via mobile devices, has been awarded a very significant ... care via EMRs to continual care via digital health. ... of key intellectual property and further secures Vivify,s position ... Vivify, launched in 2009, was the first company to ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
Breaking Medicine Technology: